Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | OGG1 | O15527 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.43 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.43 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4802830 | 0.82 | NPSR1 (0.48) | MAPTALDH1A1NPC1RAB9APKM | |
| SCHEMBL15516810 | 0.81 | MAPT (0.65) | MAPTOGG1KDM4EALDH1A1NPC1 | |
| SCHEMBL16741104 | 0.80 | PTGDR2 (0.53) | KDM4EALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL30680090 | 0.80 | PTGDR2 (0.53) | KDM4EALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL15517314 | 0.79 | LMNA (0.53) | MAPTKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL28678208 | 0.79 | MAPT (1.00) | MAPTOGG1KDM4EALDH1A1NPC1 | |
| SCHEMBL4936220 | 0.79 | RAB9A (0.63) | MAPTOGG1KDM4EALDH1A1NPC1 | |
| SCHEMBL31026266 | 0.78 | OGG1 (0.65) | MAPTOGG1KDM4EALDH1A1NPC1 | |
| SCHEMBL28815524 | 0.76 | OGG1 (0.59) | MAPTOGG1KDM4EALDH1A1NPC1 | |
| SCHEMBL15516593 | 0.75 | MAPT (0.56) | MAPTOGG1KDM4EALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2890677-B1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2017-11-15 | — | — | EP | disclosed |
| US-9447083-B2 | N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-09-20 | — | — | US | disclosed |
| US-20150252030-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-09-10 | — | — | US | disclosed |
| EP-2890677-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | Chong Kun Dang Pharmaceutical Corp. (KR) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014035149-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252030-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | MALT1, MCL1, ACIN1 | MAPT 4342/4885OGG1 2965/4885KDM4E 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.